ArticleCommunications chemistry2025
A fused deep learning approach to transform drug repositioning.
Article in Communications chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Algorithms to Assets: A Comprehensive Review of AI's Role in Preclinical Drug Discovery and the Hurdles to Clinical Translation.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Drug repositioning holds promise for discovering new therapeutic applications for existing drugs, accelerating drug development and reducing associated costs. However, current methodologies encounter difficulties in managing diverse network representations, tackling cold start issues, and handling intrinsic attribute representations. Here we introduce a Unified Knowledge-Enhanced deep learning framework for Drug Repositioning (UKEDR), which integrates knowledge graph embedding, pre-training strategies, and recommendation systems to address these challenges. To overcome the cold start issue, UKEDR utilizes a semantic similarity-driven embedding approach. Our evaluations show that UKEDR performs better than various baselines, including classical machine learning, network-based, and deep learning approaches. In cold start scenarios, it demonstrates an improved capability in handling unseen nodes and generalizing to new compounds. The model also demonstrates strong robustness on imbalanced datasets and shows excellent generalization capabilities in specific drug-centric and disease-centric cold-start scenarios, validating its potential for real-world applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.